Biotech of the week: Nordic Nanovector & its ARC technology

12/02/2016 - 1 minute

This week we say ‘au revoir’ to Nantes and head back up to the Scandinavian country that is Norway, in particular it’s capital city, Oslo – the location of our biotech of the week, Nordic Nanovector.

nordic_nanovector_logo_arc

City: Oslo, Norway

Founded: 2009

Employees: +/- 30 (as off 11/15)

Financial Data: €156M Market Cap (on 23/11/2015)

CEO: 

Missions: Betalutin, a potential new treatment of relapsed non-Hodgkin Lymphoma. NHL has been researched as it is a life-threatening blood cancer with a large unmet medical need. Currently, Betalutin is undergoing Phase I/II clinical trials, with first regulatory submission targeted in 2019.

Nordic Nanovector are hoping to target many other haematological cancers using this technology in the future.

Comment: Nanotechnology is on the rise. It could give a whole new set of tools to fight cancer. The really interesting point is that it uses more of a physical approach (radionuclide) than a chemical approach (binding to a receptor).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member